These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38467448)

  • 21. Early phase clinical trials of anticancer agents in children and adolescents - an ITCC perspective.
    Moreno L; Pearson ADJ; Paoletti X; Jimenez I; Geoerger B; Kearns PR; Zwaan CM; Doz F; Baruchel A; Vormoor J; Casanova M; Pfister SM; Morland B; Vassal G;
    Nat Rev Clin Oncol; 2017 Aug; 14(8):497-507. PubMed ID: 28508875
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Landscape of early clinical trials for childhood and adolescence cancer in Spain.
    Bautista F; Gallego S; Cañete A; Mora J; Diaz de Heredia C; Cruz O; Fernández JM; Rives S; Madero L; Castel V; Cela ME; Ramírez G; Sábado C; Acha T; Astigarraga I; Sastre A; Muñoz A; Guibelalde M; Moreno L
    Clin Transl Oncol; 2016 Jul; 18(7):708-13. PubMed ID: 26489424
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New targets and targeted drugs for the treatment of cancer: an outlook to pediatric oncology.
    Rossig C; Juergens H; Berdel WE
    Pediatr Hematol Oncol; 2011 Oct; 28(7):539-55. PubMed ID: 21936619
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of the experience with pediatric written requests issued for oncology drug products.
    Akalu AY; Meng X; Reaman GH; Ma L; Yuan W; Ye J
    Pediatr Blood Cancer; 2021 Feb; 68(2):e28828. PubMed ID: 33245181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paediatric Strategy Forum for medicinal product development of epigenetic modifiers for children: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Stegmaier K; Bourdeaut F; Reaman G; Heenen D; Meyers ML; Armstrong SA; Brown P; De Carvalho D; Jabado N; Marshall L; Rivera M; Smith M; Adamson PC; Barone A; Baumann C; Blackman S; Buenger V; Donoghue M; Duncan AD; Fox E; Gadbaw B; Hattersley M; Ho P; Jacobs I; Kelly MJ; Kieran M; Lesa G; Ligas F; Ludwinski D; McDonough J; Nikolova Z; Norga K; Senderowicz A; Taube T; Weiner S; Karres D; Vassal G
    Eur J Cancer; 2020 Nov; 139():135-148. PubMed ID: 32992153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Systematic Review of Pediatric Phase I Trials in Oncology: Toxicity and Outcomes in the Era of Targeted Therapies.
    Cohen JW; Akshintala S; Kane E; Gnanapragasam H; Widemann BC; Steinberg SM; Shah NN
    Oncologist; 2020 Jun; 25(6):532-540. PubMed ID: 31943534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Implementation of mechanism of action biology-driven early drug development for children with cancer.
    Pearson AD; Herold R; Rousseau R; Copland C; Bradley-Garelik B; Binner D; Capdeville R; Caron H; Carleer J; Chesler L; Geoerger B; Kearns P; Marshall LV; Pfister SM; Schleiermacher G; Skolnik J; Spadoni C; Sterba J; van den Berg H; Uttenreuther-Fischer M; Witt O; Norga K; Vassal G;
    Eur J Cancer; 2016 Jul; 62():124-31. PubMed ID: 27258969
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Challenging issues in pediatric oncology.
    Pui CH; Gajjar AJ; Kane JR; Qaddoumi IA; Pappo AS
    Nat Rev Clin Oncol; 2011 Jun; 8(9):540-9. PubMed ID: 21709698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Accelerating Drug Development in Pediatric Oncology With the Clinical Pharmacology Storehouse.
    Shebley M; Menon RM; Gibbs JP; Dave N; Kim SY; Marroum PJ
    J Clin Pharmacol; 2019 May; 59(5):625-637. PubMed ID: 30562405
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Next generation oncology drug development: opportunities and challenges.
    Gutierrez ME; Kummar S; Giaccone G
    Nat Rev Clin Oncol; 2009 May; 6(5):259-65. PubMed ID: 19390552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetics and oncology.
    Mummaneni P; Shord SS
    Pharmacotherapy; 2014 May; 34(5):495-505. PubMed ID: 24619798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New drug development in childhood cancer.
    Kearns P; Morland B
    Curr Opin Pediatr; 2014 Feb; 26(1):37-42. PubMed ID: 24362409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA regulatory considerations for the review of drugs intended to treat pediatric cancers and rare tumors.
    Bradford D; Singh H; Donoghue M
    Curr Opin Pediatr; 2023 Feb; 35(1):48-54. PubMed ID: 36592026
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pediatric Trials for Cancer Therapies With Targets Potentially Relevant to Pediatric Cancers.
    Hwang TJ; Orenstein L; DuBois SG; Janeway KA; Bourgeois FT
    J Natl Cancer Inst; 2020 Mar; 112(3):224-228. PubMed ID: 31665394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. New approaches to drug development in pediatric oncology.
    Adamson PC; Blaney SM
    Cancer J; 2005; 11(4):324-30. PubMed ID: 16197722
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Access to innovative therapies in pediatric oncology: Report of the nationwide experience in Canada.
    Judd S; Revon-Riviere G; Grover SA; Deyell RJ; Vanan MI; Lewis VA; Pecheux L; Zorzi AP; Goudie C; Santiago R; Tran TH; Abbott LS; Brossard J; Moorehead P; Alvi S; Portwine C; Denburg A; Whitlock JA; Cohen-Gogo S; Morgenstern DA
    Cancer Med; 2024 Feb; 13(3):e7033. PubMed ID: 38400668
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted approaches to childhood cancer: progress in drug discovery and development.
    Hirsch S; Marshall LV; Carceller Lechon F; Pearson AD; Moreno L
    Expert Opin Drug Discov; 2015 May; 10(5):483-95. PubMed ID: 25840490
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pediatric Development of Molecularly Targeted Oncology Drugs.
    Patel SK; Leong R; Zhao H; Barone A; Casey D; Liu Q; Burckart GJ; Reaman G
    Clin Pharmacol Ther; 2018 Aug; 104(2):384-389. PubMed ID: 29226303
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Importance of pharmacologic considerations in the development of targeted anticancer agents for children.
    Veluvolu SM; Grohar PJ
    Curr Opin Pediatr; 2023 Feb; 35(1):91-96. PubMed ID: 36562272
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pediatric oncology drug development and dosage optimization.
    Cheung SYA; Hay JL; Lin YW; de Greef R; Bullock J
    Front Oncol; 2023; 13():1235947. PubMed ID: 38348118
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.